
Annual report 2023
added 12-27-2025
Profound Medical Corp. EBITDA 2011-2026 | PROF
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Profound Medical Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -30.3 M | -18.9 M | -14.9 M | - | -17.2 M | -11.4 M | -9.39 M | -6.18 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.18 M | -30.3 M | -15.5 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Align Technology
ALGN
|
753 M | $ 173.14 | -0.8 % | $ 13 B | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.17 | -0.41 % | $ 1.64 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Alphatec Holdings
ATEC
|
-4.64 M | $ 10.9 | -1.54 % | $ 1.64 B | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
421 M | $ 279.25 | 0.63 % | $ 7.88 B | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.3 | -1.79 % | $ 124 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 37.59 | -1.03 % | $ 5.6 K | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 61.79 | 0.83 % | $ 91.5 B | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.61 | 0.84 % | $ 38 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 8.68 | -3.12 % | $ 246 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Electromed
ELMD
|
10.7 M | $ 24.12 | -1.19 % | $ 204 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.89 | - | $ 1.15 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Inogen
INGN
|
-9.55 M | $ 6.33 | -4.95 % | $ 168 M | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.0 | -3.86 % | $ 16.9 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 15.97 | 0.19 % | $ 375 M | ||
|
Globus Medical
GMED
|
757 M | $ 90.42 | -1.07 % | $ 12.2 B | ||
|
LivaNova PLC
LIVN
|
228 M | $ 62.78 | -0.93 % | $ 3.42 B | ||
|
LENSAR
LNSR
|
-21 M | $ 5.7 | 4.4 % | $ 68.2 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 4.11 | -0.96 % | $ 870 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
898 K | $ 10.04 | 1.62 % | $ 360 M | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 54.02 | -4.71 % | $ 1.59 B | ||
|
CONMED Corporation
CNMD
|
120 M | $ 36.74 | -0.51 % | $ 1.14 B | ||
|
Myomo
MYO
|
-13.5 M | $ 0.69 | -1.43 % | $ 28.9 M | ||
|
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 85.11 | -1.8 % | $ 2.96 B | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.68 | 0.38 % | $ 122 M | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M |